证券代码：603008 证券简称：喜临门 公告编号：2025-036 第六届董事会第九次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 喜临门家具股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日在公司 国际会议室以现场表决的方式召开第六届董事会第九次会议。本次会议通知已 于 2025 年 8 月 15 日通过电子邮件、传真、电话方式送达全体董事。 本次会议由董事长陈阿裕先生召集和主持，会议应参加董事 9 名，实际参 加会议董事 9 名。本次会议通过书面记名投票的方式进行表决，会议的召集、 召开和表决程序符合《公司法》和《公司章程》的规定，会议合法有效。 二、董事会会议审议情况 1、审议通过《2025 年半年度报告及摘要》 表决结果：同意：9 票；反对：0 票；弃权：0 票。 本议案已经公司第六届董事会审计委员会 2025 年第五次会议审议通过，并 同意提交公司董事会审议。 喜临门家具股份有限公司 报告》 表决结果：同意：9 票；反对：0 票；弃权：0 票。 具体内容详见 ...

（原标题：喜临门(603008.SH)发布上半年业绩，归母净利润2.66亿元，增长14.04%） 智通财经APP讯，喜临门(603008.SH)发布2025年半年度报告，该公司营业收入为40.21亿元，同比增长 1.59%。归属于上市公司股东的净利润为2.66亿元，同比增长14.04%。归属于上市公司股东的扣除非经 常性损益的净利润为2.6亿元，同比增长16.45%。基本每股收益为0.72元。 ...

Core Viewpoint - The company reported a revenue of 4.021 billion RMB for the first half of 2025, reflecting a year-on-year growth of 1.59% [1] - The net profit attributable to shareholders reached 266 million RMB, marking a year-on-year increase of 14.04% [1] - The net profit after deducting non-recurring gains and losses was 259 million RMB, showing a year-on-year growth of 16.45% [1] - Basic earnings per share were reported at 0.72 RMB [1] - The company plans to distribute a cash dividend of 2.80 RMB (including tax) for every 10 shares to all shareholders [1] Financial Performance - Revenue: 4.021 billion RMB, up 1.59% year-on-year [1] - Net Profit: 266 million RMB, up 14.04% year-on-year [1] - Net Profit (excluding non-recurring items): 259 million RMB, up 16.45% year-on-year [1] - Basic Earnings per Share: 0.72 RMB [1] Dividend Distribution - Proposed cash dividend: 2.80 RMB per 10 shares (including tax) [1]

Group 1 - The Ministry of Industry and Information Technology and six other departments have jointly issued implementation opinions to promote the innovation and development of the brain-computer interface (BCI) industry, aiming for breakthroughs in key technologies by 2027 and establishing an advanced technical, industrial, and standard system [1] - The introduction of this policy is seen as a significant milestone, officially recognizing BCI as an independent strategic emerging industry, which will accelerate the practical application and promotion of BCI technology in core areas such as medical rehabilitation and intelligent interaction [1][4] - The BCI technology in China is developing along two parallel paths: invasive (requiring surgical implantation) and non-invasive (collecting signals from the scalp), with sleep health emerging as a key application area for non-invasive technology [1] Group 2 - A strategic partnership has been formed between sleep technology company Xilinmen and non-invasive BCI technology firm Qiangnao Technology to explore multi-space sleep solutions based on BCI technology, creating an intelligent sleep ecosystem centered around "AI companionship" [1][2] - The world's first AI mattress incorporating BCI technology, "Baobao·BrainCo," has been launched, which monitors and analyzes users' brainwave signals in real-time to provide personalized sleep optimization solutions, marking a significant innovation in technology application [2] Group 3 - Despite the industry excitement, BCI development faces significant challenges, including the need for improved accuracy and reliability in brain signal decoding and the integration of multi-modal information from the brain, body, and environment [3] - The global BCI market is projected to reach $400 billion, but actual revenue for the industry may not exceed $1.5 billion by 2035, indicating that the BCI industry is still in its early development stage and far from commercial maturity [3] - The core competition in the BCI field lies not in market speculation but in the continuous technical challenges in laboratories and the ability to translate technology into affordable, safe, and user-centric products [4]

Group 1 - The Ministry of Industry and Information Technology and six other departments have jointly issued implementation opinions to promote the innovation and development of the brain-computer interface (BCI) industry, aiming for breakthroughs in key technologies by 2027 and establishing an advanced technical, industrial, and standard system [1] - The introduction of this document is seen as a significant milestone, officially recognizing BCI as an independent strategic emerging industry, which will accelerate the practical application and promotion of BCI technology in core areas such as medical rehabilitation and intelligent interaction [1] - The BCI technology in China is developing along two parallel paths: invasive (requiring surgical implantation) and non-invasive (collecting signals from the scalp), with non-invasive technology focusing on sleep health as a key application area [1] Group 2 - A strategic partnership has been formed between sleep technology company Xilinmen and non-invasive BCI technology firm Qiangnao Technology to explore multi-space sleep solutions based on BCI technology, creating an intelligent sleep ecosystem centered around "AI companionship" [2] - The world's first AI mattress "Baobao·BrainCo," which incorporates BCI and EEG technology, has been launched, providing personalized sleep optimization solutions through real-time monitoring and analysis of users' brainwave signals [2] Group 3 - The China Academy of Information and Communications Technology has identified two major bottlenecks in BCI technology: the need for improved accuracy and reliability in brain signal decoding, and the challenge of effectively integrating multimodal information from the brain, body, and environment [3] - Developing a universal model that can adapt to diverse populations and scenarios requires ongoing research and data accumulation, despite advancements in AI algorithms enhancing signal decoding efficiency [3] Group 4 - The global BCI market is projected to reach $400 billion, but actual revenue for the industry is expected to be less than $1.5 billion by 2035, indicating that the BCI industry is still in its early development stage and far from commercial maturity [4] - The true competitive core in the BCI field lies not in market speculation but in the continuous technical challenges faced in laboratories and the ability to transform technology into affordable, safe, and user-centric products [4] - While policy support provides direction and paves the way for the industry, the ultimate success depends on collaborative breakthroughs among academia, industry, and research [4]

然而，技术成熟度、用户隐私保护、数据安全以及如何建立普适且高效的脑电解码模型，仍是产业规模 化前必须跨越的障碍。未来脑机接口将如何更深入、更可靠地服务于人，提升生活品质，值得你我共同 关注与期待。 在不久前结束的2025世界机器人大赛——BCI脑控机器人大赛现场，参会者只需将一个"帽子"扣在头 上，就能通过意念操控屏幕上的光标或指挥机械臂完成复杂动作。无独有偶，2025世界人工智能大会 上，一名视障者头戴轻薄脑机接口设备，同样凭意念操控机械臂完成毛线编织……这些直观的演示，不 仅展示了技术可行性，更突显医院非侵入式方案在安全性和用户体验上的独特优势，为政策导向提供了 现实注脚。 在今年7月喜临门与强脑科技独家战略合作签约会上，双方发布全球首款引入脑机脑电技术的AI床垫"宝 褓·BrainCo"，通过脑波级睡眠优化直接将行业技术延伸至神经科学领域。据喜临门相关负责人透露， 未来双方的合作将进一步突破睡眠体验的空间限制，加快构建以"AI陪伴"为核心的智能睡眠生态，直 至"今夜无人失眠"美好愿景实现。 工信部等七部门7月印发《关于推动脑机接口产业创新发展的实施意见》，明确我国脑机接口技术发展 目标，提出到2027年 ...

上周，工信部等七部门印发《关于推动脑机接口产业创新发展的实施意见》，明确我国脑机接口技术发 展目标，提出到2027年，脑机接口关键技术取得突破，初步建立先进的技术体系、产业体系和标准体系 并旗帜鲜明地支持"非植入设备量产迭代"。 当马斯克的Neuralink将芯片植入渐冻症患者大脑时，中国科学家正将脑机接口技术带进日常生活。 在不久前结束的2025世界机器人大赛——BCI脑控机器人大赛现场，参会者只需将一个"帽子"扣在头 上，就能通过意念操控屏幕上的光标或指挥机械臂完成复杂动作。无独有偶，2025世界人工智能大会 上，一名视障者头戴轻薄脑机接口设备，同样凭意念操控机械臂完成毛线编织……这些直观的演示，不 仅展示了技术可行性，更突显医院非侵入式方案在安全性和用户体验上的独特优势，为政策导向提供了 现实注脚。 民生证券研报指出，应重视脑机接口研发进程关键拐点，目前标杆企业技术落地预期明确，整体行业有 望从早期阶段逐渐步入高速成长期，建议关注海外映射/有自主研发布局/有落地场景的相关企业。 其中 非侵入式脑机接口技术领军企业强脑科技成为典型代表。 业内人士认为，这一政策导向的深层逻辑在于，相比尚处探索阶段、风险与伦 ...

Core Insights - He Yuan Bio's core product, recombinant human albumin injection (Aofumin), has been approved for market launch, marking a significant milestone for the company and the industry [1][2] - The company faces challenges in converting its technological breakthroughs into sustainable commercial returns, especially given its history of losses exceeding 800 million yuan over six years [1][3] Group 1: Product and Market Dynamics - Aofumin is produced using rice endosperm as a bioreactor, utilizing gene editing technology for large-scale production, which eliminates the risks associated with animal-derived pathogens [2] - The approval of Aofumin signifies a shift from concept validation to industrialization of recombinant albumin technology in China [2] - The Chinese human albumin market is heavily reliant on imported plasma-derived products, with imports accounting for nearly 70% of the market [1][2] Group 2: Financial Performance and Challenges - He Yuan Bio reported revenues of 0.13 billion yuan, 0.24 billion yuan, and 0.25 billion yuan from 2022 to 2024, primarily from pharmaceutical excipients and research reagent services, with no drug sales revenue [3] - The company has incurred R&D expenses of 1.10 billion yuan, 1.59 billion yuan, and 1.17 billion yuan during the same period, leading to a cumulative loss of over 800 million yuan [3] - As of the end of 2024, the company's cash reserves were only 160 million yuan, indicating significant short-term debt pressure [3] Group 3: Strategic Partnerships - He Yuan Bio has formed a deep partnership with leading pharmaceutical company Betta Pharmaceuticals, which has invested 385 million yuan for a 7.6% stake and will exclusively distribute Aofumin in designated regions [4] - Betta's involvement is seen as a dual empowerment strategy, leveraging its established sales network to facilitate Aofumin's market penetration [4] - The partnership's stability is contingent on regulatory compliance and the avoidance of conflicts of interest in transactions [4] Group 4: Competitive Landscape - Competitor Tonghua Anruite has already launched a recombinant human albumin product in Russia, establishing a significant market presence with a production capacity of 50 tons per year [5] - He Yuan Bio's current production capacity is limited to 10 tons, with plans to increase to 120 tons by 2026 [5] - The market dynamics will be influenced by pricing strategies and supply chain stability, as both companies aim to establish their products in the market [5] Group 5: Market Potential and Future Outlook - The market for human albumin in China has grown from 25.8 billion yuan in 2020 to an estimated 39.5 billion yuan in 2024, with projections to exceed 57 billion yuan by 2030 [6] - The success of recombinant albumin products will depend on pricing strategies and support from payers, with potential for significant market share if costs can be managed effectively [6] - He Yuan Bio aims to enhance production efficiency and reduce costs through the establishment of an intelligent production system at its new facility [6] Group 6: Execution and Operational Challenges - The approval of Aofumin is just the beginning of He Yuan Bio's commercialization journey, which will require overcoming challenges in production capacity, market penetration, and insurance reimbursement [7] - The company must ensure stable supply from its new facility and expand its distribution network while balancing pricing and profit margins [7] - The future of He Yuan Bio will significantly impact the innovation landscape of China's biopharmaceutical industry, particularly in the context of domestic alternatives to blood products [7]

Core Points - The Shanghai Composite Index closed at 3666.44 points, slightly down by 0.46%, with a total trading volume of 23062.83 billion yuan [1] - A total of 11 A-shares have surpassed their annual line, with notable stocks showing significant deviation rates, including *ST Xinyuan at 4.65%, *ST Huarong at 4.40%, and Meihua Medical at 2.93% [1] Summary by Category Market Performance - The Shanghai Composite Index is above the annual line, indicating a positive market sentiment despite a minor decline [1] - The total trading volume for A-shares reached 23062.83 billion yuan, reflecting active market participation [1] Stocks Surpassing Annual Line - The stocks with the highest deviation rates include: - *ST Xinyuan: 11.82% increase, 19.23% turnover rate, annual line at 6.06 yuan, latest price at 6.34 yuan, deviation rate of 4.65% [1] - *ST Huarong: 4.94% increase, 0.45% turnover rate, annual line at 7.12 yuan, latest price at 7.43 yuan, deviation rate of 4.40% [1] - Meihua Medical: 3.05% increase, 14.95% turnover rate, annual line at 20.34 yuan, latest price at 20.94 yuan, deviation rate of 2.93% [1] - Other notable stocks with lower deviation rates include: - Hongtaiyang: 2.77% increase, 5.00% turnover rate, annual line at 6.86 yuan, latest price at 7.04 yuan, deviation rate of 2.60% [1] - Xi'an Catering: 3.37% increase, 9.97% turnover rate, annual line at 8.77 yuan, latest price at 8.89 yuan, deviation rate of 1.37% [1] - Supor: 1.27% increase, 0.29% turnover rate, annual line at 51.39 yuan, latest price at 51.90 yuan, deviation rate of 1.00% [1]

Core Viewpoint - The A-share market shows a slight decline with the Shanghai Composite Index at 3677.06 points, down by 0.17%, while the total trading volume reached 1,893.89 billion yuan, indicating a mixed performance among stocks breaking through the annual line [1] Group 1: Market Performance - As of 13:59 today, the Shanghai Composite Index is at 3677.06 points, with a decrease of 0.17% [1] - The total trading volume of A-shares today is 1,893.89 billion yuan [1] Group 2: Stocks Breaking Through Annual Line - A total of 16 A-shares have surpassed the annual line today, with notable stocks including *ST Xin Yuan, *ST Hua Rong, and Meihao Medical, showing significant deviation rates of 5.64%, 4.40%, and 2.63% respectively [1] - Stocks with smaller deviation rates that have just crossed the annual line include Zhongke Ruankai, Tianwei Food, and Yongzhen Co., with minimal deviation percentages [1] Group 3: Deviation Rate Rankings - The top three stocks with the highest deviation rates are: - *ST Xin Yuan: 12.87% increase, 14.89% turnover rate, annual line at 6.06 yuan, latest price at 6.40 yuan, deviation rate of 5.64% [1] - *ST Hua Rong: 4.94% increase, 0.45% turnover rate, annual line at 7.12 yuan, latest price at 7.43 yuan, deviation rate of 4.40% [1] - Meihao Medical: 2.76% increase, 12.60% turnover rate, annual line at 20.34 yuan, latest price at 20.88 yuan, deviation rate of 2.63% [1]